The blood pressure (BP) phenotypes (Ph) and comorbidities in hypertensive patients are associated with cardiovascular prognosis. The aim of this study was to investigate BPPh in medicated hypertensive patients with asthma (A) and chronic obstructive lung disease (COPD).Design and method:
The patients with hypertension (H) and A, and patients with H and COPD from routine cardiology ambulatory practice were included into the pilot study data analysis (n=63). All participants received standard antihypertensive treatment (AHT) and inhaler therapy of A/COPD. BPPh definitions: normotension (NT; clinical BP (CBP)<140/90 and ambulatory BP (ABP) 24<130/80 and ABP day<135/85 and ABP night<120/80 mmHg), masked hypertension (MH; CBP<140/90 and ABP24>129/79 and/or ABP day>134/84 and/or ABP night>119/79 mmHg), uncontrolled hypertension (UH; CBP>140/90 and ABP24>119/79 and/or ABP day>134/84 and/or ABP night>119/79 mmHg) and white coat hypertension (WCH; CBP>139/89 and ABP24<130/80 and ABP day<135/85 and ABP night<120/80 mmHg).Results:
The number of patients with H+A was 43 (14% men, mean age 63.8 ± 9.4, CBP 142,9 ± 16,7/90,1 ± 9,8 mmHg), the number of patients with H+COPD was 20 (70% men, mean age 68.3 ± 8.1, CBP 160,3 ± 19,5/91,2 ± 11,2 mmHg). BPPh in patients with H+A: NT 30%, MH 9.3%, WCH 30%, UH 32.6%. BPPh in patients with H+COPD: NT 10%, MH 0, WCH 40%, UH 50%.Conclusions:
The hypertensive patients with COPD in routine cardiology ambulatory practice are predominantly men and they older than patients with A. These patients have high CBP in 90% and may have optimal effect of AHT only in 10%. These results may indicate the poor cardiovascular prognosis of hypertensive patients with COPD in comparison patients with A.